Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD ‐11
Open accessAbstract
AIM: To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD-11 trial. MATERIALS AND METHODS: Patients were randomized to once-weekly dulaglutide 1.5 (n = 612), 3.0 (n = 616) or 4.5 mg (n = 614) for 52 weeks. The primary objective was superiority of dulaglutide 3.0 and/or 4.5 mg over 1.5 mg in HbA1c reduction at 36 weeks. Secondary and exploratory assessments included weight reduction in the overall trial population and baseline body mass index (BMI) and HbA1c subgroups. RESULTS: . At 36 weeks, dulaglutide 3.0 and 4.5 mg were superior to 1.5 mg for weight change from baseline (1.5 mg, -3.1 kg; 3.0 mg, -4.0 kg [P = .001]; 4.5 mg, -4.7 kg [P < .001]). Higher dulaglutide doses were associated with numerically greater weight reduction compared with 1.5 mg in each baseline BMI and HbA1c subgroup. Absolute weight reduction increased with increasing BMI category, but percentage weight loss was similar between subgroups. Weight reductions with dulaglutide were greater in patients with lower versus higher baseline HbA1c. CONCLUSIONS: In patients with T2D, inadequately controlled by metformin, incremental weight loss was observed with dulaglutide 1.5, 3.0 and 4.5 mg doses regardless of baseline BMI or HbA1c. Although absolute weight loss was numerically greater in patients with higher baseline BMI, percentage of weight loss was similar between BMI subgroups.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Of currently available agents, tirzepatide and semaglutide have the highest efficacy in terms of glucose lowering as well as weight loss, followed by dulaglutide, liraglutide, and extended-release exenatide.
“Of the currently available agents, tirzepatide and semaglutide have the highest efficacy in terms of glucose lowering as well as weight loss, followed by dulaglutide, liraglutide, and extendedrelease exenatide (157-161).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [159]
The Introduction and Discussion (page not specified) state that dulaglutide lowers glucose and is associated with weight loss in people with type 2 diabetes. The paper compares dulaglutide doses, but does not establish the claimed efficacy ranking against tirzepatide, semaglutide, liraglutide, or extended-release exenatide. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · see citing works
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058 · see citing works
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855 · see citing works
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · see citing works
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · see citing works
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577 · see citing works
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828 · see citing works
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · see citing works
9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Medical Care in Diabetes—2020</i>
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914 · see citing works
The science of obesity management: an endocrine society scientific statement
Bray, G. A., Heisel, W. E., Afshin, A., Jensen, M. D., Dietz, W. H., Long, M., Kushner, R. F., Daniels, S. R., Wadden, T. A., Tsai, A. G., et al. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00253 · Cited by 812 · see citing works
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493 · see citing works
Effects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352 · see citing works
Obesity, Insulin Resistance, and Cardiovascular Disease
Reaven, G. M. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.207 · Cited by 348 · see citing works
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282 · see citing works
Frias, J. P., Bonora, E., Nevarez Ruiz, L., Li, Y. G., Yu, Z., Milicevic, Z., Malik, R., Bethel, M. A., & Cox, D. A. (2021) · Diabetes Care · doi:10.2337/dc20-1473 · Cited by 199 · see citing works
Self-citationCombating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
Scheen, A. J., & Gaal, L. F. V. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70004-x · Cited by 190 · see citing works
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158 · see citing works
Giugliano, D., Maiorino, M. I., Bellastella, G., Longo, M., Chiodini, P., & Esposito, K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13847 · Cited by 153 · see citing works
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc20-s008 · Cited by 150 · see citing works
Weight Loss in Type 2 Diabetic Patients
Pi-Sunyer, X. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1526 · Cited by 100 · see citing works
Gallwitz, B., Dagogo‐Jack, S., Thieu, V., Garcia‐Perez, L., Pavo, I., Yu, M., Robertson, K. E., Zhang, N., & Giorgino, F. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13086 · Cited by 98 · see citing works
Knell, G., Li, Q., Gabriel, K. P., & Shuval, K. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.018 · Cited by 37 · see citing works
Umpierrez, G. E., Pantalone, K. M., Kwan, A. Y. M., Zimmermann, A. G., Zhang, N., & Landó, L. F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12660 · Cited by 36 · see citing works
Self-citationAroda, V. R., Capehorn, M., CHAYKIN, L. B., Frías, J. P., Lausvig, N. L., Macura, S., Lüdemann, J., Madsbad, S., Rosenstock, J., Tabak, Ö., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13896 · Cited by 32 · see citing works
Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity.
Nolen-Doerr, E., Stockman, M.-C., & Rizo, I. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00350-4 · Cited by 32 · see citing works
Matza, L. S., Boye, K. S., Currie, B. M., Paczkowski, R., Landó, L. F., Mody, R., & Jordan, J. B. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1465903 · Cited by 28 · see citing works
Self-citationThe Look AHEAD Trial: Translating Lessons Learned Into Clinical Practice and Further Study
Salvia, M. G. (2017) · Diabetes Spectrum · doi:10.2337/ds17-0016 · Cited by 27 · see citing works
Hayes, R. P., Schultz, E. M., Naegeli, A. N., & Curtis, B. H. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0123 · Cited by 21 · see citing works
Dahlqvist, S., Ahlén, E., Filipsson, K., Gustafsson, T. P., Hirsch, I. B., Tuomilehto, J., Imberg, H., Åhrén, B., Attvall, S., & Lind, M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000464 · Cited by 21 · see citing works
Hayes, R. P., & DeLozier, A. M. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0142 · Cited by 18 · see citing works
Hayes, R. P., Nelson, D. R., Meldahl, M. L., & Curtis, B. H. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0027 · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728 · see citing works
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265 · see citing works
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 302 · see citing works
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
Arslanian, S. A., Hannon, T. S., Zeitler, P. S., Chao, L. C., Boucher‐Berry, C., Pérez, M. B., Bismuth, É., Dib, S. A., Cho, J. I., & Cox, D. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204601 · Cited by 151 · see citing works
Self-citationKloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 157 · see citing works
Buddhiraju, A., Kagabo, W., Khanuja, H. S., Oni, J. K., Nikkel, L. E., & Hegde, V. V. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2024.05.079 · Cited by 84 · see citing works
Gao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., & Gu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935823 · Cited by 81 · see citing works
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68 · see citing works
Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-200 · Cited by 45 · see citing works
Papaetis, G. S., & Kyriacou, A. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/151695 · Cited by 40 · see citing works
Wei, L., Mo, W., Lan, S., Yang, H., Huang, Z., Liang, X., Li, L., Xian, J., Xie, X., Qin, Y., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/1861940 · Cited by 42 · see citing works
Papaetis, G. S. (2023) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/161170 · Cited by 40 · see citing works
Lingvay, I., Cheng, A. Y., Levine, J. A., Gomez‐Valderas, E., Allen, S. E., Ranta, K., Torcello‐Gómez, A., & Thieu, V. T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14943 · Cited by 36 · see citing works
Block, C. E. M. D., Dirinck, E. L., Verhaegen, A. A., & Gaal, L. F. V. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 31 · see citing works
Smith, W. B., Nguyen, D., Clough, T., Schofield, J. P., Kagan, M. R., Kompa, J., He, Y., Maratos–Flier, E., Jamontt, J., Vong, L., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae550 · Cited by 29 · see citing works
Guan, T., Xiao, Y., Xie, X., Meng, N., Qi, Q., Xu, J., Jiang, X., Zhang, Z., Teng, Z., & Lv, P. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03853-0 · Cited by 29 · see citing works
360-Degree Perspectives on Obesity
Cuciureanu, M. D., Caratașu, C.-C., Gabrielian, L., Frăsinariu, O. E., Checheriță, L. E., Trandafir, L. M., Stanciu, G. D., Szilagyi, A., Pogonea, I., Bordeianu, G., et al. (2023) · Medicina · doi:10.3390/medicina59061119 · Cited by 31 · see citing works
Cuda, S. E., Censani, M., Kharofa, R. Y., O’Hara, V. M., Conroy, R., Williams, D. R., Paisley, J., Browne, A. F., Karjoo, S., & Browne, N. T. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100048 · Cited by 19 · see citing works
Khan, T. T. S., Sheikh, Z., Maleknia, S. D., Oveissi, F., Fathi, A., Abrams, T., Ong, H. X., & Traini, D. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2387110 · Cited by 17 · see citing works
Katzman, J. L., Haider, M. A., Cardillo, C., Rozell, J. C., Schwarzkopf, R. M., & Lajam, C. M. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.02.042 · Cited by 15 · see citing works
Shinde, S., Thieu, V. T., Kwan, A. Y. M., Houghton, K., Meyers, J., & Schapiro, D. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01511-4 · Cited by 15 · see citing works
Self-citationGlycemic Targets and Prevention of Complications
Tsushima, Y., & Galloway, N. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae776 · Cited by 15 · see citing works
Block, C. E. M. D., Peleshok, J. C., Wilding, J. P. H., Kwan, A. Y. M., Rasouli, N., Maldonado, J. M., Wysham, C., Liu, M., Aleppo, G., & Benneyworth, B. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01660-0 · Cited by 15 · see citing works
Self-citationGlucagon‐like peptide‐1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
Bensignor, M. O., Wolf, J. M., Rudser, K. D., Kelly, A. S., & Arslanian, S. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14681 · Cited by 13 · see citing works
Ferdinand, K. C., Dunn, J. P., Nicolay, C., Sam, F., Blue, E. K., & Wang, H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01775-x · Cited by 13 · see citing works
Samajdar, S. S., Bhaduri, G., Ghoshal, P. K., Mukherjee, S., Pal, J., Chatterjee, N., & Joshi, S. (2024) · Pain Management · doi:10.1080/17581869.2024.2402214 · Cited by 12 · see citing works
Seijas‐Amigo, J., Salgado‐Barreira, Á., Castelo-Dominguez, R., Pérez-Álvarez, M. T., Ponce-Piñón, B., Fernández-Silva, M., Rodríguez-Barreiro, M., Pereira-Pía, M., Iglesias-Moreno, J. M., Gago-García, M., et al. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.05.004 · Cited by 11 · see citing works
GLP ‐1 agonists for people living with HIV and obesity, is there a potential?
Zino, L., Tack, C. J., Richel, O., & Burger, D. M. (2023) · HIV Medicine · doi:10.1111/hiv.13521 · Cited by 11 · see citing works
Alluri, A. A., Kurien, M. M., Pokar, N. P., Madarapu, A., Sadam, S., Puvvala, N., & Seetharaman, R. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0193 · Cited by 10 · see citing works
Drug-induced regeneration of pancreatic beta cells: An approach to cellular therapeutic targets
Parsi, P., Saharkhiz, S., Farani, M. R., Bakhtiyari, S., & Alipourfard, I. (2025) · Cell Regeneration · doi:10.1186/s13619-025-00255-9 · Cited by 9 · see citing works
Seo, J. Y., Lee, C. G., Choi, H. S., Lee, H. K., Lee, S. Y., Kim, H., Jung, K. Y., & Kim, J. T. (2023) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2244196.098 · Cited by 8 · see citing works
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 10 · see citing works
Han, J., Lee, W. J., Hur, K. Y., Cho, J., Lee, B., & Park, C. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0030 · Cited by 6 · see citing works
Cox, D. A., Wang, H., Nicolay, C., & Bethel, M. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14762 · Cited by 5 · see citing works
Self-citationShedding light on weight loss: A narrative review of medications for treating obesity
Darapaneni, H., Lakhanpal, S., Chhayani, H., Parikh, K., Patel, M. A., Gupta, V., Anamika, F., Munjal, R. S., & Jain, R. (2023) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2023-0023 · Cited by 4 · see citing works
Rasalam, R. R., Abdo, S., Deed, G., O’Brien, R. C., & Overland, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14953 · Cited by 5 · see citing works
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach
Yu, H., Ueckert, S., Zhou, L., Cheng, J. Y., Robertson, D. C., Hansen, L. B., Flor, A., Parker, V., Hamrén, B., & Khan, A. A. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13194 · Cited by 4 · see citing works
De la découverte des hormones incrétines aux doubles et triples agonistes GIP / GLP-1 / glucagon
Phan, F., Bertrand, R., Amouyal, C., & Andréelli, F. (2024) · médecine/sciences · doi:10.1051/medsci/2024153 · Cited by 3 · see citing works
January, S. E., Fester, K. A., Escamilla, J. E., & Cano, M. (2025) · Clinical Transplantation · doi:10.1111/ctr.70246 · Cited by 3 · see citing works
Zhu, D., Ma, J., Wang, W., Shi, B., Dong, X., Bian, F., Li, Q., Wang, Y., Jiang, C., Wang, X., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06593-2 · Cited by 3 · see citing works
Duong, A., Heacock, S., Amering, S., Brennan, L., Venci, J. V., & Acquisto, N. M. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231199852 · Cited by 2 · see citing works
Sauter, E. R., & Agurs‐Collins, T. (2024) · Cancers · doi:10.3390/cancers16193275 · Cited by 2 · see citing works
Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
Overholser, A., Czech, E. J., Speer, L., Wilson, J., & Overholser, A. (2025) · Translation The University of Toledo Journal of Medical Sciences · doi:10.46570/utjms-2024-1218 · Cited by 1 · see citing works
Luo, Y., Ding, B., Xia, W., Liu, B., Ge, S., Lü, Y., & Ma, J. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02665-7 · Cited by 1 · see citing works
Alpert, Z., Katzman, J. L., Lajam, C. M., Schwarzkopf, R. M., & Rozell, J. C. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.08.068 · Cited by 1 · see citing works
Jia, W., Jiang, F., Xu, Y., Li, Y., Bao, Y., & WANG, Q. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70112 · Cited by 1 · see citing works
Elrggal, M. E., Elkeraie, A. F., Carriazo, S. M., Sawaf, H., Khor, S. Y., Elkeraie, Y., Haddad, I. R., Moustafa, K., & Hassanein, M. M. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070009 · Cited by 1 · see citing works
Vashisht, R., Dhruva, S. S., Patel, A. R., Dahm, L., Morris, P., Gonzalez, D. M., Follett, R., Sirota, M., Singh, K., Han, C., et al. (2025) · medRxiv · doi:10.1101/2025.08.13.25333579 · Cited by 1 · see citing works
Pharmacologic Therapy for Type 2 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch04
Pharmacologic Therapy for Type 1 Diabetes
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch01
Ferdinand, K. C., Dunn, J., Nicolay, C., Sam, F., Blue, E. K., & Wang, H. (2023) · Figshare · doi:10.6084/m9.figshare.22624691
Katzman, J. L., Alpert, Z., Kennedy, M., Rozell, J. C., Schwarzkopf, R. M., & Lajam, C. M. (2026) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-025-06167-2
Mallette, J. H., Speed, J. S., Lirette, S. T., Moore, D., & Clemmer, J. S. (2026) · Obesity · doi:10.1002/oby.70180
Brady, A., Roopnarinesingh, R. C., Craig, R., & Bampoe, S. (2026) · Research Square · doi:10.21203/rs.3.rs-9197869/v1
Xu, J., Zhou, A., Xu, M., Chen, Q. W., Xu, C., Li, J., Li, N., Li, Z., Wu, G., Zhang, W., et al. (2026) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.6c00052
Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes
Buros‐Stein, A., PAULEY, M. E., & Snell‐Bergeon, J. K. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.003
Ikonomidis, I., Michalopoulou, E., Pavlidis, G., Nikolaou, P., Katogiannis, K., Prentza, V., Thymis, J., Vlachomitros, D., Katsanaki, E., Kostelli, G., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004311
Samajdar, S. S., Joshi, S., SABOO, B., Mukherjee, S., & Misra, A. (2026) · Diabetology International · doi:10.1007/s13340-026-00910-9
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
Pharmacological Interventions for Management of Obesity in Ageing
Sathaye, S., & Pathak, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_20
A Practical Perspective on Confronting the Obesity Epidemic: Public-Health Strategies
Durma, A. C., & Czupryniak, L. (2026) · Nutrients · doi:10.3390/nu18162602
Chen, J. J., Chiru, E.-D., & Shen, S. (2026) · Current Breast Cancer Reports · doi:10.1007/s12609-026-00662-0
Hassan, A., Farooq, Q. U. A., Parwesh, F., Rasul, M., Masood, A., Aftab, H., Riaz, H., Mahmood, A., Malik, M. A., Rehman, A. U., et al. (2026) · F1000Research · doi:10.12688/f1000research.186847.1
GLP-1 Receptor Agonists and Reproductive Health
Porterfield, F., Mulligan, J., Salim, K., Olubowale, O. O., & Stanford, F. C. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.07.003
(2026) · ADA Clinical Compendia · doi:10.2337/db20261-33
Sharata, E. E., Abdel-Samea, A. S., Reda, Y., Abdelnaser, M., Rofaeil, R. R., & Mohyeldin, R. H. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02757-2
GLP‐1 Receptor Agonists and Cancer Risk in Obesity Treatment
Hofseth, L. J., Murphy, E. A., Playdon, M. C., Makowski, L., Ibele, A. R., Fairman, C. M., & Hébert, J. R. (2026) · Obesity Reviews · doi:10.1111/obr.70247
- Authors
- Bonora, E., Frias, J. P., Tinahones, F. J., Van, J., Malik, R. E., Yu, Z., Mody, R., Bethel, A., Kwan, A. Y. M., & Cox, D. A.
- Affiliations
- University of Verona (IT)
- National Research Institute Los Angeles California USA
- Instituto de Salud Carlos III (ES)
- Diabetes Research Center Tustin California USA
- Eli Lilly (United States) (US)
- Corresponding author
- Cox, David A.
- ORCID
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2021-06-29
- Volume
- 23
- Issue
- 10
- Pages
- 2242-2250
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- PMC
- PMC8518850
- OpenAlex
- W3174970167
- Cited by
- 67
- References
- 31
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 11 · 2023: 12 · 2022: 13
- FWCI
- 6.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Obesity and Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by-nc-nd)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dulaglutide, type 2 diabetes, weight loss, dose-response relationship, GLP-1 receptor agonists, body mass index, HbA1c
- MeSH terms
- Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Middle Aged, Recombinant Fusion Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
